Receptor Comparison# Weight Loss Efficacy# Retatrutide Phase 2 Results# The Phase 2 obesity trial (Jastreboff et al., NEJM 2023
Risks and considerations for microdosing semaglutide Microdosing semaglutide can have the following side effects: Lack of clinical evidence, safety data, and FDA approval Microdosing semaglutide is not recommended by the FDA for weight management or glycemic control
We grew up hearing about it for immunity, for fighting colds, and later, for brightening the skin
The majority of clinical investigations conducted thus far are characterized by limited sample sizes, abbreviated intervention periods, and diverse study designs, thereby complicating the establishment of optimal dosing regimens, timing of administration, and the effective combinations of these therapeutic modalities
A 9-week, placebo-controlled study of 48 adults with alcohol use disorder demonstrated that once-weekly semaglutide reduced alcohol self-administration in the laboratory (, 0.48 [95% CI, 0.85 to 0.11];P = .01), craving (, 0.39 [95%CI, 0.73 to 0.06];P = .01), and drinks per drinking day (, 0.41 [95% CI, 0.73 to 0.09]
